Drug intelligence / Profile preview

BK60106

Development stage
Unknown
Lead developer
Georgetown University
01

Overview

BK60106: sourced facts only. name: "Among 26 new derivatives, we identified two compounds, BK50164 and BK60106, that cause cell death specifically in ES primarily due to inhibition of CD99 but not via inhibition of DNA synthesis." [PMID:36917882]; target: "Among 26 new derivatives, we identified two compounds, BK50164 and BK60106, that cause cell death specifically in ES primarily due to inhibition of CD99 but not via inhibition of DNA synthesis." [PMID:36917882]; developer: "Chemistry Department, Georgetown University, Washington, DC, 20057, USA; Medicinal Chemistry Shared Resource (MCSR), Georgetown University Medical Center, Washington, DC, USA." [PMID:36917882]

02

Targets

CD99 (CD99 molecule)

Beyond the preview

Go deeper on BK60106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK60106.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call